Baytril Otic. Drop 15ml

Baytril Otic is used to treat outer ear infections in dogs. Unlike oil or petroleum-based products, Baytril Otic is water-based which helps to sooth inflamed ears. Baytril requires a prescription from your veterinarian.

Key Benefits

The dual power of enrofloxacin and silver sulfadiazine

• Enrofloxacin provides rapid bactericidal activity against the bacteria found most often in canine otitis externa: Coagulase-positive Staphylococcus, Pseudomonas aeruginosa, Enterobacter, Proteus mirabilis, Aeromonas hydrophila, Streptococcus, and Klebsiella pneumoniae.
• Silver sulfadiazine (SSD) is a highly effective antimycotic, killing the fungal organisms most commonly associated with otitis externa: Malassezia pachydermatis, Candida albicans and Aspergillus.
• SSD also has broad-spectrum antibacterial activity against many Gram negative and Gram positive organisms, including Pseudomonas aeruginosa.
• SSD is a non-irritating topical antimicrobial that may enhance epidermal repair by reducing inflammation.

The power of a convenient formulation

• Baytril Otic (enrofloxacin/silver sulfadiazine) is an elegant water-based emulsion that is soothing to infected ears. The drop formulation of Baytril Otic provides excellent penetration into ear canals, delivering high concentrations of active ingredients to the site of infection.
• Petroleum-based otic preparations can be messy and inconvenient for pet owners to administer. Water-based solutions, such as Baytril; Otic, are preferred over oil-based products for treatment of purulent otic infections. Occlusive ointments and oils should be avoided for yeast infections, where they may promote growth of these organisms.

The power of flexible therapy

• Because Baytril Otic contains no corticosteroids, therapy can be tailored to the needs of the individual patient, with or without adjunctive steroid use; allowing the veterinarian to prescribe the exact amount and duration of anti-inflammatory therapy desired.
• Baytril Otic provides safe therapy for sensitive ear tissues, avoiding potential effects of prolonged use of corticosteroids.2 During clinical trials less than 2% of dogs exhibited local hypersensitivity of the aural epithelium.

The power of Baytril (enrofloxacin) inside and out

• A study demonstrated that 82% of dogs with chronic otitis externa had concurrent otitis media.3 71% of these dogs had intact tympanic membranes.
• The combined power of Baytril Otic and Baytril Tablets will provide rapid penetration of otic tissues and elimination of bacteria both in otitis externa and externa media.
• Safety of Baytril Otic (enrofloxacin/silver sulfadiazine) has not been established in patients with perforated tympanic membranes. Patients with otitis media will also require systemic therapy. Baytril (enrofloxacin) Tablets have proven efficacy against the organisms commonly associated with middle ear infections, Staphylococcus intermedius and Pseudomonas.
• Quinolone class drugs should be used with caution in animals with known or suspected Central Nervous System disorders.

How it works

Baytril Otic works to treat ear infections with the use of two ingredients enrofloxacin and silver sulfadiazine. Enrofloxacin has quick bacteria-killing properties and silver sulfadiazine is an ingredient which kills fungal microogranisms most commonly associated with canine otitis externa (ear infections).

Indications:

Baytril Otic is indicated as a treatment for canine otitis externa complicated by bacterial and fungal organisms susceptible to enrofloxacin and/or silver sulfadiazine.

View Baytril Otic Drug Facts Sheet.

Shake well before each use.

Tilt head so that the affected ear is presented in an upward orientation. Administer a sufficient quantity of Baytril Otic to coat the aural lesions and the external auditory canal. As a general guide, administer 5-10 drops per treatment in dogs weighing 35 lbs. or less and 10-15 drops per treatment in dogs weighing more than 35 lbs. Following treatment, gently massage the ear so as to ensure complete and uniform distribution of the medication throughout the external ear canal. Apply twice daily for a duration of up to 14 days.

Caution:

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Effectiveness:

Due to its combination of active ingredients, Baytril Otic provides antimicrobial therapy against bacteria and fungi (which includes yeast) commonly encountered in cases of canine otitis externa.

The effectiveness of Baytril Otic was evaluated in a controlled, double-blind, multi-site clinical trial. One hundred and sixty-nine dogs (n=169), with naturally occurring active otitis externa participated in the study. The presence of active disease was verified by aural cytology, microbial culture and otoscopy/clinical scoring. Qualified cases were randomly assigned to either Baytril Otic treatment (n=113) or to a comparable placebo-based regimen (n=56). Treatments were administered twice daily for up to 14 days. Assessment of effectiveness was based on continued resolution of clinical signs 3 to 4 days following administration of the last dose.

At study conclusion, Baytril Otic was found to be a significantly more effective treatment for canine otitis externa than the placebo regimen. Based on the scoring system used to assess treatment response, therapeutic success occurred in 67% of Baytril Otic treated infections compared to 14% with placebo (r-value²0.001) after 14 days of treatment.

Contraindications:

Baytril Otic is contraindicated in dogs with suspected or known hypersensitivity to quinolones and/or sulfonamides.

Human Warnings:

Not for human use. Keep out of the reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation develops or persists following ocular or dermal exposures. Individuals with a history of hypersensitivity to quinolone compounds or antibacterials should avoid handling this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight.

Precautions:

The use of Baytril Otic in dogs with perforated tympanic membranes has not been evaluated. Therefore, the integrity of the tumpanic membrane should be evaluated before administering this product. If hearing or vestibular dysfunction is noted during the course of treatment, discontinue use of Baytril Otic. Quinolone class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures.

Quinolone class drug have been associated with cartilage erosions in weight bearing joints and other forms of arthropathy in immature animals of various species.

The safe use of Baytril Otic in dogs used for breeding purposes, during pregnancy, or in lactating bitches, has not been evaluated.

Adverse Reactions:

During clinical trials, 2 of 113 (1.7%) dogs exhibited reactions that may have resulted from treatment with Baytril Otic. Both cases displayed local hypersensitivity responses of the aural epithelium to some component within the Baytril Otic formulation. The reactions were characterized by acute inflammation of the ear canal and pinna.

Safety:

General Safety Study:

In a target animal study, Baytril Otic was administered in both ears of 24 clinically normal beagle dogs at either recommended or exaggerated dosages: 10, 30 or 50 drops applied twice daily for 42 consecutive days. A control group of 8 beagle dogs was treated by administering 50 drops of vehicle in one ear twice daily for 42 consecutive days, with the contralateral ear untreated. Erythema was noted in all groups, including both treated and untreated ears in the controls, which resolved following termination of treatment.

Oral safety Study:

In order to test safety in case of ingestion, Baytril Otic was administered, twice daily for 14 consecutive days, to the dorsum of the tongue and to the left buccal mucosa of 6 clinically normal dogs. No adverse local or systemic reactions were reported.